This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
Adult patients (≥18 years).
Biopsy-confirmed C3G.
Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.
None
Adult patients with a diagnosis of C3G who have received at least one dose of iptacopan through an EAP from 01 October 2020 through 30 June 2025.
Cohort
Retrospective
Not listed
Baseline Demographics
Height
Weight
Blood Pressure
Systolic and diastolic blood pressure.
UPCR FMV During Iptacopan Treatment
UPCR-24h During Iptacopan Treatment
UPCR from 24-hour collection.
Proteinuria-24h During Iptacopan Treatment
Total protein excretion from 24-hour collection.
Urine Albumin-to-Creatinine Ratio (UACR) FMV During Iptacopan Treatment
Click on the lead sponsor to view all of their trials.
